Imfinzi for stage III NSCLC that cannot be removed by surgery (PACIFIC study). On average, people who were treated with Imfinzi lived 16.8 months before their cancer got worse.

Imfinzi, which is used to treat some types of cancer, can cause side effects. Learn about common, mild, and serious side effects and how to manage them.

Imfinzi (durvalumab), which is used to treat some cancers, can cause side effects. Learn more about Imfinzi's side effects, such as cough, rash, and hair loss.

Imfinzi is given by a health care professional in a hospital or clinic. It is given as an infusion into a vein (intravenously). It usually takes about an hour to receive your dose of Imfinzi.

IMFINZI is also approved in the US, the EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer (ES-SCLC) based on the CASPIAN Phase ...

Imfinzi and Tecentriq are both drugs used to treat certain cancers. Learn how they’re similar and different to help you decide if one may be right for you.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

Based on AEGEAN Phase III trial results which showed IMFINZI-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone WILMINGTON, Del ...

At data cutoff, 67.7% of patients in the Imfinzi arm and 67.5% in the placebo arm were still receiving study treatment. In the PD-L1 expression of 25% or more group, the median age was 65 years versus ...

A treatment combination of Imjudo (tremelimumab) and Imfinzi (durvalumab) demonstrated improved survival outcomes, including disease control and treatment responses in patients with unresectable ...

The FDA based its decision on the company’s phase 3 Niagara trial. At an interim analysis, the Imfinzi regimen prompted a 32% reduction in the risk of a basket of negative events, including ...

IMFINZI in combination with chemotherapy followed by olaparib and IMFINZI is approved for patients with mismatch repair proficient advanced or recurrent endometrial cancer in EU and Japan. Since the ...